Akebia’s Phase IIb AKB-6548 anaemia trial meets primary endpoint

US-based biopharmaceutical firm Akebia Therapeutics has reported positive top-line results from its Phase IIb placebo-controlled trial of its once-daily, oral therapy, AKB-6548, in non-dialysis patients with anaemia related to chronic kidney disease …
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news